Pharvaris N.V.

6 days ago · defenseworld.net

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the completion of the transaction, the insider owned 56,450 shares in the company, valued

6 days ago · defenseworld.net

Squarepoint Ops LLC lowered its stake in Pharvaris N.V. (NASDAQ: PHVS) by 53.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,629 shares of the company's stock after selling 51,755 shares during the period. Squarepoint Ops LLC owned approximately 0.07% of Pharvaris

6 days ago · seekingalpha.com

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

7 days ago · zacks.com

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

13 days ago · seekingalpha.com

Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p

14 days ago · seekingalpha.com

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript

14 days ago · reuters.com

Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting ​the main goal of a late-stage trial.

1 month ago · globenewswire.com

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second quarter ending on June 30, 2026, and provided a business update.

2 months ago · globenewswire.com

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experiences of people with AAE-C1INH and validating relevant patient-reported outcome (PRO) measures have been published in Frontiers in Immunology. The study findings directly informed the design of and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) investigating deucrictibant for the prophylaxis and on-demand treatment of AAE-C1INH attacks.

2 months ago · zacks.com

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.